Company Overview and News

 
An evening walk down Dalal Street | A volatile end to the week, Sensex falls 279 pts; DHFL tanks 45%

6h moneycontrol
A largely volatile day has come to a close, with indices ending the day on a negative note. However, they are off the day’s low points. The Nifty has managed to give up 11,200 in today’s trade. The Sensex has closed over 200 points lower.
BHRYY 532617 511288 535789 534816 INFRATEL LHFLY 500253 GRAVITA SBAZ GRUH YESBANK KMBKY 511072 533282 IDKQY JETAIRWAYS GRHFY 532648 YYBKY IBULHSGFIN DHFL LICHSGFIN KOTAKBANK 500247

 
Jet Airways crashes to 52-week low of Rs 225

8h thehindubusinessline
Jet Airways’ shares continued to fall for the second straight session on Friday, down 8 per cent, due to concerns over I-T officials conducting a survey of its premises.
YESBANK 532617 532648 JETAIRWAYS YYBKY

 
GP Rai, Acting chairman, Mormugao Port Trust: Connectivity has to be rethought, and we have done that

10h freepressjournal.in
Mormugao is Goa’s oldest port that is accorded major port status since 1963. Goa has faced some decline in industrial activity after the Supreme Court’s ban on mining since 2012. But the port is still quite relevant in the region. The deputy chairman of Mormugao Port Trust, Guruprasad Rai, who is also acting chairman of the company, outlines the challenges and growth plans of the port. Rai, who has a career spanning nearly three decades, talks to Pankaj Joshi and R N Bhaskar about his vision for the port.
532617 JETAIRWAYS

 
Jet Airways says I-T officials conducting survey since September 19

10h livemint
New Delhi: Jet Airways on Friday said income-tax officials had been conducting the survey of its premises since September 19.
532617 JETAIRWAYS

 
Jet Airways customer demands Rs 30 lakh compensation, 100 upgrades

11h moneycontrol
One of the five Jet Airways passengers who were sent to a city hospital for treatment, has demanded Rs 30 lakh in compensation, besides 100 upgrade vouchers, alleging lack of proper care by the airline, sources in the airline have said.
532617 JETAIRWAYS

 
Jet Airways touches 52-week low after I-T inspects co#39;s books

12h moneycontrol
Shares of Jet Airways touched 52-week low of Rs 224.70, down 8 percent intraday Friday after Income tax investigation department conducted survey on companies premises.
532617 JETAIRWAYS

 
Jet Privilege can actually get higher valuation than Jet Airways

14h livemint
Jet Airways (India) Ltd said it would monetize its 49% stake in Jet Privilege Pvt. Ltd, the frequent-flyer loyalty programme subsidiary. News reports suggest the associate company will be valued at ₹ 3,000-4,000 crore. While Jet Airways’ market capitalisation is about ₹ 3,000 crore, after adding its net debt, the airline’s enterprise value would be at ₹ 10,000 crore. That’s just about 0.4 times its consolidated revenue.
532617 JETAIRWAYS

 
Civil Aviation Minister Suresh Prabhu orders safety audit of all airlines, airports

14h moneycontrol
Civil Aviation Minister Suresh Prabhu Thursday ordered a safety audit of all scheduled airlines and airports, amid recent incidents related to safety of passengers.
532617 JETAIRWAYS

 
Jet Airways (India) Limited - News Clarification

14h nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
532617 JETAIRWAYS

 
Jet Airways mid-air horror: When a plane crashed on cabin pressure loss in Greece

15h freepressjournal.in
New Delhi: More than 13 years ago, a Boeing aircraft crashed in a hilly terrain in Greece snuffing out 121 lives. A year later, investigators concluded that omissions in controlling cabin pressure was a key reason for the crash. On Thursday morning, the 166 passengers on board a Jet Airways flight might not have been aware about the incident that happened in Greece over a decade ago. But, they faced a similar situation as the cockpit crew “forgot” to control cabin pressure.
532617 JETAIRWAYS

 
Worried Jet Airways lenders likely to seek faster loan repayments

15h livemint
Mumbai: A consortium of overseas lenders to Jet Airways (India) Ltd may ask the airline to expedite the repayment of loans worth $150 million amid its deteriorating financial health, two people directly aware of the matter said, requesting anonymity. A letter on behalf of the lenders was sent by Dubai-based Mashreq Bank to Jet Airways on Monday seeking a detailed response by 24 September. Mashreq Bank was the arranger to the loan.
ICICIBANK PNJZY 532461 532174 IBN 532617 PNB JETAIRWAYS

 
Passengers suffer nosebleeds after aircraft loses cabin pressure

19h abc.net.au
Dozens of passengers on an Indian domestic flight have complained of nosebleeds and ear pain when the aircraft suddenly lost cabin pressure after leaving Mumbai.
532617 JETAIRWAYS

Related Articles

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...

EKSO: Ekso Bionics Holdings Analysis and Research Report

2018-09-18 - Asif

Overview The company design, develop and sell exoskeleton technology to augment human strength, endurance and mobility. The company's exoskeleton technology serves multiple markets and can be used both by able-bodied users as well as by persons with physical disabilities. Ekso Bionics has sold, rented or leased devices that (a) enable individuals with neurological conditions affecting gait (stroke and spinal cord injury) to rehabilitate and to walk again and (b) allow industrial workers to perform heavy duty work for extended periods. Today, its medical exoskeleton, Ekso GT, is used as a rehabilitation tool to allow physicians and therapists to rehabilitate patients who have suffered a stroke or spinal cord injury. With its unique features designed specifically for hospitals and its proprietary SmartAssist software, Ekso GT allows for the early mobilization of patients, with high step count and high dosage treatments. The intent is to allow the patient’s central nervous syst...

AGRX: Agile Therapeutics Analysis and Research Report

2018-09-18 - Asif

Overview Agile Therapeutics is a forward-thinking women’s healthcare company dedicated to fulfilling the unmet health needs of today’s women. Twirla® and its other current potential product candidates are designed to provide women with contraceptive options that offer greater convenience and facilitate compliance. The company's lead product candidate, Twirla, also known as AG200-15, is a once-weekly prescription contraceptive patch that is at the end of Phase 3 clinical development. Since its inception in 1997, Agile Therapeutics has devoted substantial resources to developing Twirla, building its intellectual property portfolio, business planning, raising capital and providing general and administrative support for these operations. The company incurred research and development expenses of $14.4 million, $20.9 million and $25.6 million during the years ended December 31, 2017, 2016 and 2015, respectively. The company incurred research and development expenses of $2.4 milli...